CD274 and non-small cell lung carcinoma: Along the same lines, other ICIs such as pembrolizumab (a humanized IgG4 anti-PD-1 mAb) and atezolizumab (a humanized IgG1 anti-PD-L1 mAb), marked a second breakthrough in the treatment of NSCLC due to their demonstrated efficacy over docetaxel in second-line settings.